Compare BBNX & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBNX | CCCC |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | 423 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.1M | 404.7M |
| IPO Year | N/A | 2020 |
| Metric | BBNX | CCCC |
|---|---|---|
| Price | $14.61 | $3.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $23.80 | $12.20 |
| AVG Volume (30 Days) | 780.1K | ★ 2.9M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | $34.90 | N/A |
| Revenue Next Year | $34.63 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $8.80 | $1.36 |
| 52 Week High | $32.71 | $4.60 |
| Indicator | BBNX | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 71.48 | 54.33 |
| Support Level | $9.34 | $2.13 |
| Resistance Level | $15.53 | $3.89 |
| Average True Range (ATR) | 0.96 | 0.38 |
| MACD | 0.27 | -0.05 |
| Stochastic Oscillator | 91.73 | 31.95 |
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.